MX357491B - Co-diferenciacion de los monocitos a partir de donantes alogenicos. - Google Patents
Co-diferenciacion de los monocitos a partir de donantes alogenicos.Info
- Publication number
- MX357491B MX357491B MX2015007800A MX2015007800A MX357491B MX 357491 B MX357491 B MX 357491B MX 2015007800 A MX2015007800 A MX 2015007800A MX 2015007800 A MX2015007800 A MX 2015007800A MX 357491 B MX357491 B MX 357491B
- Authority
- MX
- Mexico
- Prior art keywords
- allogeneic
- monocytes
- differentiation
- allogeneic donors
- donors
- Prior art date
Links
- 230000000735 allogeneic effect Effects 0.000 title abstract 8
- 210000001616 monocyte Anatomy 0.000 title abstract 3
- 210000004443 dendritic cell Anatomy 0.000 abstract 3
- 210000000265 leukocyte Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método de producción de células dendríticas inmaduras no agotadas (DCs) procedentes de dos diferentes donantes alogénicos. En el método, se proporciona una mezcla de leucocitos alogénicos, cuyos leucocitos alogénicos han sido obtenidos a partir de al menos dos donantes alogénicos diferentes. Posteriormente, los monocitos alogénicos se aíslan de la mezcla de leucocitos alogénicos. A partir de entonces, las DCs inmaduras no agotadas se generan a partir de dicho monocitos alogénicos aisladas. Un método de producción de DCs pro-inflamatorias, que comprende las etapas de: proporcionar DCs inmadura no agotadas, activar las DCs inmaduras no agotadas para obtener DCs pro-inflamatorias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12197687 | 2012-12-18 | ||
| PCT/EP2013/077139 WO2014096033A1 (en) | 2012-12-18 | 2013-12-18 | Co-differentiation of monocytes from allogeneic donors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015007800A MX2015007800A (es) | 2016-01-12 |
| MX357491B true MX357491B (es) | 2018-07-11 |
Family
ID=47427250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007800A MX357491B (es) | 2012-12-18 | 2013-12-18 | Co-diferenciacion de los monocitos a partir de donantes alogenicos. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9714413B2 (es) |
| EP (2) | EP2788474B1 (es) |
| JP (1) | JP6529439B2 (es) |
| KR (1) | KR102148051B1 (es) |
| CN (2) | CN110042081B (es) |
| AU (1) | AU2013360793B2 (es) |
| BR (1) | BR112015014270B1 (es) |
| CA (1) | CA2895280C (es) |
| DK (2) | DK2788474T3 (es) |
| ES (2) | ES2591230T3 (es) |
| HU (2) | HUE027619T2 (es) |
| MX (1) | MX357491B (es) |
| PL (2) | PL2788474T3 (es) |
| RU (1) | RU2668816C2 (es) |
| SI (2) | SI2788474T1 (es) |
| WO (1) | WO2014096033A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3460052B1 (en) | 2017-09-20 | 2019-10-30 | Immunicum AB | Improved allogeneic dendritic cells for use in cancer treatment |
| US12329807B2 (en) | 2018-01-18 | 2025-06-17 | Meganano Biotech, Inc. | Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases |
| CN108660125A (zh) * | 2018-05-14 | 2018-10-16 | 武汉博百欧生物科技有限公司 | 一种从人体输血废弃物中提取中性粒细胞嗜天青颗粒的方法 |
| WO2020154424A1 (en) * | 2019-01-22 | 2020-07-30 | The Brigham And Women's Hospital, Inc. | Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2394831A1 (en) * | 2000-01-11 | 2001-07-19 | Maxygen, Inc. | Monocyte-derived dendritic cell subsets |
| AU2002326463A1 (en) | 2001-07-25 | 2003-02-17 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
| SI1509244T1 (sl) | 2002-06-06 | 2011-11-30 | Immunicum An | Nov postopek in spojina za izdelavo celične alogenične vakcine |
| KR100585456B1 (ko) * | 2003-09-30 | 2006-06-07 | 국립암센터 | 동종 종양-관련 항원이 탑재된 수지상세포, 이의 제조방법및 이를 유효성분으로 하는 암 치료용 백신 조성물 |
| CA2504451A1 (en) * | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
| KR20220113543A (ko) * | 2005-12-08 | 2022-08-12 | 노쓰웨스트 바이오써라퓨틱스, 인크. | 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법 |
| EP1806395A1 (en) * | 2006-01-06 | 2007-07-11 | Stichting Sanquin Bloedvoorziening | Maturation of dendritic cells |
| EP1840206A1 (en) * | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Compositions for the preparation of mature dendritic cells |
| EP2494038B1 (en) * | 2009-10-27 | 2019-06-26 | Immunicum AB | Method for proliferation of antigen-specific t cells |
| PL2534242T3 (pl) * | 2010-02-10 | 2016-11-30 | Polepszona kompozycja do hamowania proliferacji komórek nowotworowych | |
| JP2014511704A (ja) * | 2011-04-13 | 2014-05-19 | イミュニカム・エイビイ | Ｔ細胞のプライミングのための方法 |
| CN103502439B (zh) * | 2011-04-13 | 2016-10-12 | 因缪尼卡姆股份公司 | 用于抗原特异性t细胞增殖的方法 |
-
2013
- 2013-12-18 SI SI201330066T patent/SI2788474T1/sl unknown
- 2013-12-18 BR BR112015014270-2A patent/BR112015014270B1/pt not_active IP Right Cessation
- 2013-12-18 CN CN201910284719.5A patent/CN110042081B/zh not_active Expired - Fee Related
- 2013-12-18 JP JP2015547082A patent/JP6529439B2/ja active Active
- 2013-12-18 AU AU2013360793A patent/AU2013360793B2/en not_active Ceased
- 2013-12-18 PL PL13814106T patent/PL2788474T3/pl unknown
- 2013-12-18 SI SI201330281A patent/SI2913394T1/sl unknown
- 2013-12-18 RU RU2015119164A patent/RU2668816C2/ru active
- 2013-12-18 CA CA2895280A patent/CA2895280C/en active Active
- 2013-12-18 PL PL15161369.2T patent/PL2913394T3/pl unknown
- 2013-12-18 DK DK13814106.4T patent/DK2788474T3/en active
- 2013-12-18 ES ES15161369.2T patent/ES2591230T3/es active Active
- 2013-12-18 EP EP13814106.4A patent/EP2788474B1/en active Active
- 2013-12-18 EP EP15161369.2A patent/EP2913394B1/en active Active
- 2013-12-18 KR KR1020157015766A patent/KR102148051B1/ko not_active Expired - Fee Related
- 2013-12-18 CN CN201380066722.0A patent/CN105452449B/zh not_active Expired - Fee Related
- 2013-12-18 WO PCT/EP2013/077139 patent/WO2014096033A1/en not_active Ceased
- 2013-12-18 MX MX2015007800A patent/MX357491B/es active IP Right Grant
- 2013-12-18 HU HUE13814106A patent/HUE027619T2/en unknown
- 2013-12-18 ES ES13814106.4T patent/ES2548229T3/es active Active
- 2013-12-18 HU HUE15161369A patent/HUE028895T2/en unknown
- 2013-12-18 US US14/653,184 patent/US9714413B2/en active Active
- 2013-12-18 DK DK15161369.2T patent/DK2913394T3/en active
-
2017
- 2017-06-15 US US15/623,530 patent/US10626371B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
| MX2017007538A (es) | Sintesis de ácido nucleíco de volúmen pequeño, alta eficiencia. | |
| PH12015500040B1 (en) | Supercritical hydrolysis of biomass | |
| EP3201343A4 (en) | High efficiency, high throughput generation of genetically modified mammals by electroporation | |
| IN2014CN04160A (es) | ||
| MX366112B (es) | Medio de cultivo celular y metodos de produccion de anticuerpos. | |
| MX392317B (es) | Proceso para la preparación de etilenglicol a partir de azúcares. | |
| MX2014002996A (es) | Anticuerpos anti - egfr/anti - igf-1r bisespecificos. | |
| MX2021006732A (es) | Nanoemulsiones para bebidas producidas mediante un proceso de alto cizallamiento. | |
| WO2016033437A3 (en) | Polyethers, polyamines, polythioethers, and methods for making same | |
| GEP201706626B (en) | Synthesis of (s)-nifuratel | |
| EA201391081A1 (ru) | Способ получения оксида этилена | |
| PH12019501676A1 (en) | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one | |
| IN2014DN08412A (es) | ||
| MX2015007800A (es) | Co-diferenciacion de los monocitos a partir de donantes alogenicos. | |
| MX2016013897A (es) | Proceso de produccion de gasolina que comprende una etapa de isomerizacion seguida de al menos dos etapas de separacion. | |
| MY161804A (en) | Peroxide blends for the accelerated crosslinking of ethylene vinyl acetate | |
| EA201491803A1 (ru) | Способ получения окиси этилена | |
| PH12014501327A1 (en) | Processes for making magnolol analogs | |
| IN2014CH00151A (es) | ||
| PH12014501367A1 (en) | Processes for making magnolol and derivatives thereof | |
| GEP201706708B (en) | Isoxazolidine derivatives | |
| AU2012248013B2 (en) | Intermediate for synthesizing caspofungin and preparation method therefor | |
| MX2014003936A (es) | Procedimiento para preparar ditiina-tetracarboximidas. | |
| WO2014207019A8 (de) | Verfahren zur herstellung von 1,3-butandiol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |